Significant controversy persists in clinical practice regarding whether the optimal treatment strategy for metastatic ALK-positive NSCLC should initiate with second-generation ALK-TKIs or proceed directly to third-generation TKIs as first-line therapy. Here, ALK is linked to non-small cell lung carcinoma.